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A variety of screening tests have been used to predict
the development of chronic graft-versus-host disease
(GVHD) in patients who survive the ﬁrst 4 months after a
bone marrow transplantation [1,2] We have analyzed addi-
tional follow-up data from a previously published study [1]
of chronic GVHD outcome to determine whether tests can
predict overall survival among patients who had no clinical
manifestations of chronic GVHD at the time of the screen-
ing studies and no recurrent malignancy. The screening
studies were interpreted between days 71 and 115 (median,
day 90). The study cohort consisted of 241 patients who
received methotrexate and cyclosporine for GVHD prophy-
laxis. First, a Cox regression base model was constructed
with high- versus low-risk categories for pretransplantation
diagnosis, total body irradiation (TBI) dose (>1200 cGy TBI
versus ≤1200 cGy TBI versus no TBI), age (≥40 years versus
<40 years), and donor relationship/histocompatibility type
(unrelated or HLA-mismatched related donor versus HLA-
matched relative) as shown in Table 1. 
We then determined whether screening test results con-
tributed any additional information to the multivariable
model after taking into account the factors shown in Table 1.
In this analysis, an abnormal Schirmer’s test result, an ele-
vated alkaline phosphatase level, and a low platelet count
were correlated with an increased risk of mortality (Table 2).
The association of a positive Schirmer’s test with
increased mortality could be a reflection of illnesses other
than GVHD. Medications, gonadal failure, and radiation can
cause ocular sicca. This complication has been reported in
20% of autologous transplant recipients and in 47% of allo-
geneic transplant recipients [3]. Similarly, an elevated alkaline
phosphatase level often indicates liver dysfunction and could
represent drug toxicity, infection, or other complications.
A previous study [4] showed that thrombocytopenia was
associated with an increased risk of mortality among
patients with extensive clinical chronic GVHD. Our current
results suggest that thrombocytopenia is associated with an
increased risk of mortality after BMT even without exten-
sive clinical chronic GVHD. Thrombocytopenia could
reﬂect an undiagnosed viral infection or another serious sys-
temic illness.
Conversely, perhaps all of these tests are associated with
an increased mortality because they represent an ongoing
undetected chronic GVHD that is associated with an
immune deficiency. This immune deficiency could predis-
pose patients to fatal infections. The positive test results
could be associated with undetected chronic GVHD in
combination with other factors. Study of a larger cohort and
analysis of the causes of death might yield further insights
that could explain the higher mortality associated with
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Table 1. Relative Risk of Nonsurvival After BMT Using the Cox 
Multivariable Regression Base Model 
Factor Relative Risk (95% CI) P
Pretransplantation diagnosis 3.2 (2.0-5.3) <.001
TBI dose 1.2 (0.89-1.5) .27
Patient age 1.9 (1.2-3.1) .01
Donor relationship/histocompatibility 1.4 (0.79-2.7) .23
Table 2. Assessment of Screening Tests in a Multivariable Analysis of Mortality*
P†
Screening Test Relative Risk (95% CI) Wald LRT
Oral examination 
Positive versus negative 1.3 (0.78-2.2) .31
Lip biopsy
Positive versus negative 0.78 (0.47-1.3) .36 
Not done versus negative 1.4 (0.64-3.1) .39
.35
Skin biopsy 
Positive versus negative 0.96 (0.58-1.6) .87 
Schirmer’s test‡ 
Positive versus negative 2.2 (1.3-3.7) .005 
Not done versus negative 3.2 (1.5-7.0) .003
.002
Alkaline phosphatase 
>120 IU versus normal 2.2 (1.2-4.1) .02
AST 
>50 IU versus normal 0.99 (0.57-1.7) .99
Bilirubin
>1.2 mg/dL versus normal 0.81 (0.47-1.4) .46 
Serum IgG 
<500 mg/dL versus normal 0.67 (0.30-1.5) .34 
Not done versus normal 0.86 (0.43-1.7) .66 .63
Platelets 
<100,000/µL versus ≥100,000/µL 1.7 (1.0-2.8) .03
*LRT indicates likelihood ratio test; AST, asparte transaminase.
†LRT p-values were derived from the likelihood ratio test of the
screening test variable contribution to the model in Table 1. Wald test
p-values are additionally included for the comparison of individual lev-
els to the indicated baseline for the three screening tests with more
than two categories.
‡The Schirmer’s test was deﬁned as abnormal when the mean value
was ≤10 mm at 5 minutes.
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thrombocytopenia, an elevated alkaline phosphatase level,
and an abnormal Schirmer’s test in this study population.
John L. Wagner, Mary E.D. Flowers, 
Gary Longton, Rainer Storb, Paul Martin
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University of Washington School of Medicine, Seattle, Washington
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